Job Description
At Bristol Myers Squibb, we are inspired by a single vision – transforming patients’ lives through science. In oncology, hematology, immunology and cardiovascular disease – and one of the most diverse and promising pipelines in the industry – each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
Functional Area Description
The Early Clinical Development function is part of a global scientific organization dedicated to initial evaluations of new molecules, biomarkers, and mechanistic hypotheses in humans. The group drives early clinical strategy, and the design, execution, and interpretation of studies to select the most promising drug candidates for later development.
Serve as the clinical point of accountability for the Development Team and responsible for the overall clinical development plan for asset(s) in one or more indication(s)
Demonstrate matrix leadership to develop, motivate and achieve results through teams; enable development of a resilient attitude, embrace change and have an unwavering commitment to organizational People Strategy
Ensure studies are designed to meet regulatory, quality, medical, and access goals
Medical Monitoring
Serves as an independent Medical Monitor for clinical trials from Phase 1 through Proof-of-Concept by
Articulating clinical development strategy
Analyzing, interpreting, and acting on clinical trial data towards development
Serving as principal functional author for Regulatory submissions, study reports, and publications
Independently synthesizes and/or contributes to plans (e.g., trial design, development strategy, regulatory strategy) based on merging data and multi-functional input
Designs and develops clinical studies and research plans in support of asset strategy with the Early Clinical Development Leadership team; clinical studies include first-in-human Phase I, proof of concept Phase I/II, entry registrational studies, biomarker qualification studies, and/or clinical pharmacology studies
Clinical Development Expertise & Strategy
Manages multiple/complex active programs concurrently across early development clinical lifecycles
Accountable for clinical contribution to the development of indication strategy
Partners with Worldwide Patient Safety physicians in the ongoing review of safety data
Provides clinical leadership and disease area expertise into integrated disease area strategies
Partners closely with KOLs in specific indications
Evaluates strategic options against a given Target Product Profile (TPP)
Collaborates with Global Development Operations/Global Compliance Group to develop asset level risk management plan, resolves issues with Quality/Clinical Scientists, and raises to Development Team as needed
Sets executional priorities and partners with Clinical Scientists to support executional delivery of studies
Accountable for top line data with support of Clinical Scientists and Statisticians
Liaises with Clinical Scientists, Translational & Discovery Scientists, and Development Teams to define dose and schedule, indications, and patient selection (e.g., biomarker qualification and implementation)
Liaises with other functions (e.g., Thematic Research Centers and Translational Medicine) and apply foresight and prioritize translational objectives in anticipation of development needs
Ad-Hoc involvement in various departmental or enterprise initiatives (e.g., committees, sub-teams etc.)
Presents and/or articulates clinical strategy to senior leadership and to support progression of portfolio
Health Authority Interactions
Serves as primary clinical representative in regulatory interactions for early development projects
Accountable for clinical contributions to clinical study reports (CSRs), regulatory reports, briefing books and submission documents
External Partnerships, Alliances, and Publications
Acts as a focal point for defining and establishing relationships with key Global Phase I Centers
Sits in team responsible for establishing key alliances with academic centers, co-operative groups, vendors and government agencies
Represents department in business development due diligence and partner alliance management as appropriate; sits on JDC/JRC/JSC as appropriate
Track record or recognized for contributions to field (e.g., publications, patents, keynote participation in conferences etc.)
Leadership and Matrix Management
May be responsible for managing Early Clinical Development Physicians, attracting, developing and retaining top talent; ensures appropriate training and mentoring of Early Clinical Development Physicians
Champions a quality-focused mindset and ensures adherence to GCP and compliance obligations for clinical conduct
Degree Requirements
Advanced degree(s) in relevant field: MD or MD/PhD and deep clinical expertise in a therapeutic area
Fellowship/specialty training in relevant therapeutic area preferred
Experience Requirements
7+ years of relevant experience in discovery, translational and/or clinical research in academic or industry setting including education where applicable
Extensive experience in clinical trial design and execution, biomarker development, and development strategy in pharmaceutical industry
Deep understanding of pharmaceutical discovery, development and commercialization
Track record of mentorship and/or management and/or matrix leadership
Demonstrated leadership abilities in a matrix environment
Key Competency Requirements
Excellent skills in clinical development strategy including the clinical components of regulatory submission(s)
External focus to understand the trends in the disease area treatment paradigms and ability to build relationships with external partners, thought leaders and collaborators outside of BMS
Partner and interact with colleagues from Late Development to assure a seamless transition into late stage (Phase II-III trials)
Domestic and International travel may be required
Summit, NJ
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.